Antrastuin (trastuzumab biosimilar) / Anhui Anke Biotech - LARVOL DELTA

Anke Biotech's trastuzumab was approved for marketing. Anhui's independent R&D and industrialization of antibody drugs achieved a 'zero' breakthrough [Google translation] (Anke Bio Press Release) - "...trastuzumab for injection independently developed by Anhui Anke Bioengineering (Group) Co., Ltd. was officially approved for marketing. This is Anke Biotech’s first deployment in the field of anti-tumor targeted drugs. products, after more than 10 years of research and development, nearly 1 billion yuan has been invested in research and development....This product, with the trade name 'Acetin', is a macromolecule targeted anti-tumor drug with a product specification of 150 mg. It is mainly used to treat HER2-positive early breast cancer, HER2-positive metastatic breast cancer and HER2-positive metastatic gastric cancer."

Non-US regulatory • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2